

Role of endoscopy in the staging and management of colorectal cancer

This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this text. In preparing this guideline, a search of the medical literature was performed by using PubMed. Additional references were obtained from the bibliographies of the identified articles and from recommendations of expert consultants. When limited or no data exist from well-designed prospective trials, emphasis is given to results from large series and reports from recognized experts. Guidelines for appropriate use of endoscopy are based on a critical review of the available data and expert consensus at the time that the guidelines are drafted. Further controlled clinical studies may be needed to clarify aspects of this guideline. This guideline may be revised as necessary to account for changes in technology, new data, or other aspects of clinical practice. The recommendations were based on reviewed studies and were graded on the strength of the supporting evidence (Table 1).¹ This guideline is intended to be an educational device to provide information that may assist endoscopists in providing care to patients. This guideline is not a rule and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment. Clinical decisions in any particular case involve a complex analysis of the patient's condition and available courses of action. Therefore, clinical considerations may lead an endoscopist to take a course of action that varies from these guidelines.

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in American men and women and the second leading cause of cancer death.² This updated ASGE guideline focuses on the role of endoscopy in the staging and treatment of CRC. Recommendations for CRC screening and surveillance are discussed in previous documents by the Multi-Society Task Force endorsed by the ASGE.^{3,4}

This article had an error in the print version (see the erratum in the September 2013 issue of GIE); the article posted here is the corrected version.

Copyright © 2013 by the American Society for Gastrointestinal Endoscopy
0016-5107/\$36.00
<http://dx.doi.org/10.1016/j.gie.2013.04.163>

PRESURGICAL LOCALIZATION

Colonoscopy has an important role in the localization of malignant lesions for subsequent identification at the time of surgery. Preoperative endoscopic marking can be helpful in localizing flat, small, or subtle colonic lesions that may be difficult to identify by inspection or palpation during surgery. Marking techniques currently available include endoscopic tattooing and metallic clip placement.⁵⁻⁷ Tattoos with India ink are visible at surgery for up to 5 months.⁵ No guidelines exist on the optimal placement of tattoos or metallic clips; therefore, close communication with surgical colleagues involved in the subsequent resection is important.

STAGING OF RECTAL CANCER

CRC is staged according to the TNM system established by the American Joint Committee on Cancer (Table 2).⁸ The primary clinical impact of staging rectal cancer is to differentiate T1N0 or T2N0 disease from T3 or TxN1-2 disease, for which chemoradiation is recommended in addition to surgical resection.⁹ Several meta-analyses have evaluated the staging accuracy of EUS,¹⁰⁻¹³ and some have compared the accuracy of EUS with that of magnetic resonance imaging (MRI) and CT.^{10,11} In general, EUS was found to exhibit high sensitivity (80%-96%) and specificity (75%-98%) for the staging of T0 to T3 disease.¹⁰⁻¹³ EUS may have higher T-staging accuracy than other cross-sectional imaging tests,¹⁰ but nodal staging accuracy was modest for EUS (67% sensitivity, 78% specificity) and not statistically different among the 3 imaging modalities.^{10,11} MRI may also have a role in guiding surgery because it shows the anatomic relationship between rectal tumors and the pelvic floor and sacrum. Correctly differentiating benign from malignant perirectal lymphadenopathy by EUS is difficult because inflammatory nodes may be present in the setting of rectal cancer; however, EUS-guided FNA (EUS-FNA) of perirectal lymph nodes may be helpful when the presence of nodal metastasis would change patient management.¹⁴ The accuracy of EUS may be subject to publication bias and should be viewed with some caution.¹⁵ In clinical practice, other imaging modalities may have comparable staging accuracy. A 2011 prospective study of 90 subjects found a T2 staging accuracy of 76% to 77% for both EUS and MRI and T3 staging accuracy of 76% for EUS and 83%

TABLE 1. GRADE system for rating the quality of evidence for guidelines¹

Quality of evidence	Definition	Symbol
High quality	Further research is very unlikely to change our confidence in the estimate of effect	⊕⊕⊕⊕
Moderate quality	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate	⊕⊕⊕○
Low quality	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate	⊕⊕○○
Very low quality	Any estimate of effect is very uncertain	⊕○○○

TABLE 2. TNM staging classification of colorectal cancer

Primary tumor (T)	
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ: intraepithelial or invasion of lamina propria
T1	Tumor invades submucosa
T2	Tumor invades muscularis propria
T3	Tumor invades through the muscularis propria into the subserosa or into nonperitonealized pericolic or perirectal tissues
T4	Tumor directly invades other organs or structures and/or perforates visceral peritoneum
Regional lymph nodes (N)	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in 1-3 regional lymph nodes
N2	Metastasis in ≥4 regional lymph nodes
Distant metastasis (M)	
MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

for MRI ($P > .05$). MRI did not visualize any T1 tumors, and EUS understaged all T4 tumors in that series.¹⁶ The finding of a nontraversable malignant stricture in the rectum may be predictive of advanced tumor stage (T3, T4, or Tx, N1 or 2) and should be locally staged by radiographic cross-sectional imaging.^{17,18} The reported accuracy of EUS restaging after neoadjuvant chemoradiation has been modest to poor: 38% to 75% for T staging and 57% to 84% for N staging.¹⁹⁻²⁵ A prospective study of 90 subjects comparing CT, MRI, and EUS for T and N staging after neoadjuvant therapy found similarly low accuracy for all 3 modalities. T staging accuracy was 37% by CT, 34% by MRI, and 27% by EUS. N staging was 62% by CT, 68% by MRI, and 65% by EUS.

ENDOSCOPIC MANAGEMENT OF MALIGNANT COLONIC OBSTRUCTION

Endoscopic management of malignant obstruction is discussed in a recent ASGE Standards of Practice document.²⁶ Endoscopic alternatives to surgical decompression include placement of a self-expandable metal stent (SEMS), tumor debulking, and placement of a decompression tube. Even with successful endoscopic decompression, early surgical consultation is recommended because patients may deteriorate rapidly. Endoscopy should not be performed in patients with peritoneal signs or suspicion of perforation. Colonic SEMS may also be used as a “bridge to surgery” for patients with malignant obstruction who are surgical candidates. The success rate of single-stage elective

surgery after colonic SEMS placement for decompression is 60% to 85%.²⁷ The major adverse events associated with colonic SEMS placement include obstruction, migration, and perforation.²⁸ In addition, dilation after colonic SEMS placement should be avoided because of the associated risk of perforation.²⁸

ENDOSCOPIC RESECTION OF COLORECTAL NEOPLASIA

In general, flat and polypoid lesions found at the time of colonoscopy should be removed.²⁹ Pedunculated lesions are usually removed by using standard snare polypectomy. Pedunculated polyps with cancer confined to the submucosa and without evidence of unfavorable histological factors have a 0.3% risk of cancer recurrence or lymph node metastasis after complete endoscopic removal, and surgery is not necessary.³⁰

For pedunculated polyps with unfavorable histological features (<1 mm cancer-free margin, poor histological differentiation, vascular or lymphatic invasion), invading the submucosa of the bowel wall below the polyp's stalk, or extending through the submucosa into the deeper wall

layers, surgery is recommended because endoscopic removal is unlikely to be curative.³¹⁻³³ The site of resection of such polyps should be inked with a tattoo to facilitate identification during surgery. In all cases of potential surgical referral, the risk of recurrent disease should be weighed against the operative risk in individual patients.

Endoscopic removal of larger sessile or flat lesions may require more advanced techniques. EMR and endoscopic submucosal dissection (ESD) are reviewed in a 2008 ASGE Technology Status Evaluation Report.³⁴ EMR is indicated for sessile or flat neoplastic lesions confined to the mucosa or submucosa of the colon. Lesions that are 2 cm or smaller can often be removed en bloc, whereas larger lesions may require piecemeal resection. Typically, a solution is injected into the submucosa to lift the lesion for easier removal and to provide a cushion to help protect the deeper layers of the bowel wall from mechanical or electrocautery damage. The inability to raise the base of a polyp after submucosal solution injection can indicate the presence of cancer invading deep into the submucosa and precludes endoscopic resection of the lesion.^{35,36} Lesions that do not lift can be technically difficult to remove by EMR even if the cause of the nonlifting sign is not invasive malignancy (eg, from fibrosis from a previous biopsy or previous attempts at endoscopic resection).³⁷ Therefore, EMR should be attempted only if complete resection of neoplastic lesions is anticipated.

ESD was developed for en bloc resection of larger lesions (ie, >2 cm). After submucosal injection of a fluid cushion, the lesion is dissected from the deep layers of the bowel wall by using electrocautery knives. The adverse events of EMR and ESD in the removal of colorectal lesions are reviewed in a previous ASGE document.²⁸ The major adverse events are the same as those for standard polypectomy (ie, bleeding and perforation); however, the rate is higher.²⁸ The role of ESD for colorectal lesions is not well established. Compared with its use for gastric lesions, ESD in the colon is more technically challenging because of less space, difficult positioning, thinner bowel wall, and the presence of colonic folds.³⁴ EMR is widely used to remove benign flat neoplastic lesions in the colon including those with high-grade dysplasia. EMR can also be definitive treatment for intramucosal (T1mN0) CRC in which the risk of lymph node involvement is negligible.^{31,33,38,39}

The optimal technique to minimize the risk of residual neoplasia during piecemeal EMR is evolving. Residual polyp tissue may have contributed to previous reports of interval cancers after colonoscopy with polypectomy.^{4,40} In general, the most important principle is to maximize potential for complete eradication on the initial resection attempt. This may necessitate referral to a center with expertise in advanced polypectomy. All visible adenomatous tissue should be endoscopically resected or ablated if snare excision is not feasible. Techniques to minimize residual

polyp tissue include taking a small margin of surrounding mucosa at the polyp edges⁴¹ or tissue ablation. Tissue ablation has been described both prophylactically at the resection margins after a piecemeal removal and for the treatment of endoscopically visible residual polypoid tissue. Ablation techniques have been primarily described with argon plasma coagulation (APC),⁴²⁻⁴⁴ with 1 report of diathermy ablation with the snare tip.⁴¹ Estimates of short-term (2-6 months) residual/recurrence rates after piecemeal EMR are broad, ranging from 0% to 55%.⁴⁵ Late recurrence (after 12 months) is less common, occurring in less than 5% in 1 study.⁴⁵ A small, randomized study evaluating the use of prophylactic APC at piecemeal polypectomy sites where complete excision was thought to be achieved by the endoscopist produced a lower risk of recurrence in the APC group (1/10 vs 7/11, $P = .02$), that was statistically significant.⁴² In a larger, more recent study of 479 patients with 514 colonic lesions evaluating the safety and efficacy of EMR, use of APC was an independent predictor of recurrence after presumed effective EMR.⁴¹ The authors of this study reported a 20% recurrence rate and did not prophylactically treat the polyp edges with APC, reserving APC for visible tissue not amenable to snare excision.

Regardless of the technique used, close surveillance after piecemeal polypectomy is mandatory given the potential for recurrence. To facilitate surveillance, tattooing should be considered for polyps that cannot readily be identified by anatomic landmarks. A detailed review of endoscopic tattooing is available in a 2010 ASGE Technology Status Evaluation Report.⁵ Ideally, the tattoo should be distinct from the polypectomy site to avoid fibrotic tissue reaction that can be associated with tattooing agents. No guidelines exist on the optimal placement of a tattoo, but some experts have suggested standardizing a tattoo injection to 3 cm downstream from the lesion.⁴¹ Photodocumentation of the polypectomy site in relation to the area of tattoo may be helpful during subsequent surveillance examinations to allow for accurate identification of the scar site if no visible tissue is found. Guidelines recommend a follow-up colonoscopy in 2 to 6 months after piecemeal EMR of large sessile lesions, with both endoscopic and pathological assessments to ensure complete removal.^{4,40} One retrospective study found that on the first follow-up surveillance endoscopy, a normal endoscopic appearance of the polypectomy site and negative scar biopsy specimens were predictive of long-term eradication in 97.9% of such cases.⁴⁵

Surgery should be considered for sessile lesions removed piecemeal that are found to be malignant because the adequacy of the resection margin cannot be determined.⁴⁶ Malignant lesions with submucosal invasion are associated with a 6% to 12% risk of lymph node metastasis and should also be managed surgically.⁴⁷⁻⁵¹ EMR should not be used for ulcerated lesions or lesions that do not lift.³⁴

RECOMMENDATIONS

- We recommend removal of suspected neoplastic lesions at the time of colonoscopy when not contraindicated and as technical expertise allows. ⊕⊕⊕⊕
- We recommend EUS in the preoperative locoregional staging of rectal cancer to guide therapy. ⊕⊕⊕○
- We recommend weighing the risk of recurrence against the individual's operative risk in all cases in which surgery is being considered as a treatment for CRC. ⊕⊕⊕○
- We recommend surgical management of all malignant polyps with unfavorable histological features if the patient is an appropriate surgical candidate. ⊕⊕⊕○
- We recommend that pedunculated polyps found to contain cancer confined to the submucosa of the polyp or stalk and with favorable histological features be managed endoscopically. ⊕⊕⊕○
- We recommend surgery for sessile or flat colonic neoplasia that demonstrates submucosal invasion if the patient is an appropriate surgical candidate. ⊕⊕⊕○
- We suggest surgical management for sessile or flat colonic neoplasia that is determined to be malignant after piecemeal endoscopic resection if the patient is an appropriate surgical candidate. ⊕⊕○○
- We recommend EMR only be attempted if complete resection of neoplastic lesions is anticipated. ⊕⊕⊕○

DISCLOSURES

The following authors disclosed financial relationships relevant to this publication: Dr Fisher, consultant to Epigenomics Inc; Dr Hwang, on the speakers' bureau of Novartis, consultant to U.S. Endoscopy, and received a grant from Olympus; Dr Fanelli, owner/director of New Wave Surgical and on the advisory board of Via Surgical; Dr Khabab, consultant to, receives honoraria from, and on the advisory board of Boston Scientific; Dr Chathadi, on the speakers' bureau of Boston Scientific; Dr Muthusamy, consultant to Boston Scientific. The other authors disclosed no financial relationships relevant to this publication.

Abbreviations: APC, argon plasma coagulation; CRC, colorectal cancer; ESD, endoscopic submucosal dissection; EUS-FNA, EUS-guided FNA; MRI, magnetic resonance imaging; SEMS, self-expandable metal stents.

REFERENCES

1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. *CA Cancer J Clin* 2010;60:277-300.
3. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology* 2008;134:1570-95.
4. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2012;143:844-57.
5. Kethu SR, Banerjee S, Desilets D, et al. Endoscopic tattooing. *Gastrointest Endosc* 2010;72:681-5.
6. Kim SH, Milsom JW, Church JM, et al. Perioperative tumor localization for laparoscopic colorectal surgery. *Surg Endosc* 1997;11:1013-6.
7. Montorsi M, Opocher E, Santambrogio R, et al. Original technique for small colorectal tumor localization during laparoscopic surgery. *Dis Colon Rectum* 1999;42:819-22.
8. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 2010;17:1471-4.
9. Engstrom PF, Arnoletti JP, Benson AB 3rd, et al. NCCN Clinical practice guidelines in oncology: rectal cancer. *J Natl Compr Canc Netw* 2009;7:838-81.
10. Bipat S, Glas AS, Slors FJ, et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. *Radiology* 2004;232:773-83.
11. Lahaye MJ, Engelen SM, Nelemans PJ, et al. Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. *Semin Ultrasound CT MR* 2005;26:259-68.
12. Puli SR, Bechtold ML, Reddy JB, et al. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. *Dig Dis Sci* 2010;55:1221-9.
13. Puli SR, Bechtold ML, Reddy JB, et al. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. *Ann Surg Oncol* 2009;16:254-65.
14. Harewood GC, Wiersema MJ, Nelson H, et al. A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer. *Gastroenterology* 2002;123:24-32.
15. Harewood GC. Assessment of publication bias in the reporting of EUS performance in staging rectal cancer. *Am J Gastroenterol* 2005;100:808-16.
16. Fernandez-Esparrach G, Ayuso-Colella JR, Sendino O, et al. EUS and magnetic resonance imaging in the staging of rectal cancer: a prospective and comparative study. *Gastrointest Endosc* 2011;74:347-54.
17. Miyamoto S, Boku N, Fujii T, et al. Macroscopic typing with wall stricture sign may reflect tumor behaviors of advanced colorectal cancers. *J Gastroenterol* 2001;36:158-65.
18. Van Dam J, Rice TW, Catalano MF, et al. High-grade malignant stricture is predictive of esophageal tumor stage. Risks of endosonographic evaluation. *Cancer* 1993;71:2910-7.
19. Fleshman JW, Myerson RJ, Fry RD, et al. Accuracy of transrectal ultrasound in predicting pathologic stage of rectal cancer before and after preoperative radiation therapy. *Dis Colon Rectum* 1992;35:823-9.
20. Huh JW, Park YA, Jung EJ, et al. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. *J Am Coll Surg* 2008;207:7-12.
21. Napoleon B, Pujol B, Berger F, et al. Accuracy of endosonography in the staging of rectal cancer treated by radiotherapy. *Br J Surg* 1991;78:785-8.
22. Pastor C, Subtil JC, Sola J, et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? *Dis Colon Rectum* 2011;54:1141-6.
23. Radovanovic Z, Breberina M, Petrovic T, et al. Accuracy of endorectal ultrasonography in staging locally advanced rectal cancer after preoperative chemoradiation. *Surg Endosc* 2008;22:2412-5.
24. Rau B, Hunerbein M, Barth C, et al. Accuracy of endorectal ultrasound after preoperative radiochemotherapy in locally advanced rectal cancer. *Surg Endosc* 1999;13:980-4.

25. Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. *Am J Gastroenterol* 2004;99:109-12.
26. Harrison ME, Anderson MA, Appalaneni V, et al. The role of endoscopy in the management of patients with known and suspected colonic obstruction and pseudo-obstruction. *Gastrointest Endosc* 2010;71:669-79.
27. Varadarajulu S, Banerjee S, Barth B, et al. Enteral stents. *Gastrointest Endosc* 2011;74:455-64.
28. Fisher DA, Maple JT, Ben-Menachem T, et al. Complications of colonoscopy. *Gastrointest Endosc* 2011;74:745-52.
29. Rex DK, Bond JH, Winawer S, et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. *Am J Gastroenterol* 2002;97:1296-308.
30. Cranley JP, Petras RE, Carey WD, et al. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma? *Gastroenterology* 1986;91:419-27.
31. Morson BC, Whiteway JE, Jones EA, et al. Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy. *Gut* 1984;25:437-44.
32. Muller S, Chesner IM, Egan MJ, et al. Significance of venous and lymphatic invasion in malignant polyps of the colon and rectum. *Gut* 1989;30:1385-91.
33. Nascimbeni R, Burgart LJ, Nivatvongs S, et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. *Dis Colon Rectum* 2002;45:200-6.
34. Kantsevov SV, Adler DG, Conway JD, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. *Gastrointest Endosc* 2008;68:11-8.
35. Kanamori T, Itoh M, Yokoyama Y, et al. Injection-incision-assisted snare resection of large sessile colorectal polyps. *Gastrointest Endosc* 1996;43:189-95.
36. Uno Y, Munakata A, Tanaka M. The discrepancy of histologic diagnosis between flat early colon cancers and flat adenomas. *Gastrointest Endosc* 1994;40:1-6.
37. Kobayashi N, Saito Y, Sano Y, et al. Determining the treatment strategy for colorectal neoplastic lesions: endoscopic assessment or the non-lifting sign for diagnosing invasion depth? *Endoscopy* 2007;39:701-5.
38. Fujimori T, Kawamata H, Kashida H. Precancerous lesions of the colorectum. *J Gastroenterol* 2001;36:587-94.
39. Matsuda T, Gotoda T, Saito Y, et al. Our perspective on endoscopic resection for colorectal neoplasms. *Gastroenterol Clin Biol* 2010;34:367-70.
40. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. *Gastroenterology* 2006;130:1872-85.
41. Moss A, Bourke MJ, Williams SJ, et al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. *Gastroenterology* 2011;140:1909-18.
42. Brooker JC, Saunders BP, Shah SG, et al. Treatment with argon plasma coagulation reduces recurrence after piecemeal resection of large sessile colonic polyps: a randomized trial and recommendations. *Gastrointest Endosc* 2002;55:371-5.
43. Regula J, Wronska E, Polkowski M, et al. Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study. *Endoscopy* 2003;35:212-8.
44. Zlatanich J, Wayne JD, Kim PS, et al. Large sessile colonic adenomas: use of argon plasma coagulator to supplement piecemeal snare polypectomy. *Gastrointest Endosc* 1999;49:731-5.
45. Khashab M, Eid E, Rusche M, et al. Incidence and predictors of "late" recurrences after endoscopic piecemeal resection of large sessile adenomas. *Gastrointest Endosc* 2009;70:344-9.
46. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol* 2000;95:3053-63.
47. Cooper HS. Surgical pathology of endoscopically removed malignant polyps of the colon and rectum. *Am J Surg Pathol* 1983;7:613-23.
48. Kyzer S, Begin LR, Gordon PH, et al. The care of patients with colorectal polyps that contain invasive adenocarcinoma. Endoscopic polypectomy or colectomy? *Cancer* 1992;70:2044-50.
49. Matsuda T, Saito Y, Fujii T, et al. Size does not determine the grade of malignancy of early invasive colorectal cancer. *World J Gastroenterol* 2009;15:2708-13.
50. Minamoto T, Mai M, Ogino T, et al. Early invasive colorectal carcinomas metastatic to the lymph node with attention to their nonpolypoid development. *Am J Gastroenterol* 1993;88:1035-9.
51. Nusko G, Mansmann U, Partzsch U, et al. Invasive carcinoma in colorectal adenomas: multivariate analysis of patient and adenoma characteristics. *Endoscopy* 1997;29:626-31.

Prepared by:
 ASGE STANDARDS OF PRACTICE COMMITTEE
 Deborah A. Fisher, MD
 Amandeep K. Shergill, MD
 Dayna S. Early, MD
 Ruben D. Acosta, MD
 Vinay Chandrasekhara, MD
 Krishnavel V. Chathadi, MD
 G. Anton Decker, MD
 John A. Evans, MD
 Robert D. Fanelli, MD, SAGES Representative
 Kimberly Q. Foley, RN, SGNA Representative
 Lisa Fonkalsrud, RN, SGNA Representative
 Joo Ha Hwang, MD
 Terry Jue, MD
 Mouen A. Khashab, MD
 Jenifer R. Lightdale, MD
 V. Raman Muthusamy, MD
 Shabana F. Pasha, MD
 John R. Saltzman, MD
 Ravi Sharaf, MD
 Brooks D. Cash, MD (Committee Chair)

This document is a product of the Standards of Practice Committee. This document was reviewed and approved by the Governing Board of the American Society for Gastrointestinal Endoscopy.
